Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CB 03

X
Drug Profile

CB 03

Alternative Names: CB 04; CB-003 - Zhimeng Biopharma; CB-03; CB-04 - Zhimeng Biopharma; CB03-154

Latest Information Update: 03 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zhimeng Biopharma
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Small molecules
  • Mechanism of Action KCNQ2 potassium channel stimulants; KCNQ3 potassium channel stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Epilepsy
  • Preclinical Amyotrophic lateral sclerosis; Depressive disorders; Stroke
  • No development reported Pain

Most Recent Events

  • 30 Sep 2024 Shanghai Zhimeng Biopharma plans a phase II trial for Partial epilepsies (Adjunctive treatment) in September 2024 (NCT06612775)
  • 28 Mar 2024 No recent reports of development identified for preclinical development in Pain in China
  • 12 Feb 2024 356394- Trial completion added in KDM and HE

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top